

Noel W Clarke

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/1329855/noel-w-clarke-publications-by-year.pdf>

Version: 2024-04-19

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

132
papers

8,356
citations

45
h-index

90
g-index

156
ext. papers

10,261
ext. citations

7.1
avg, IF

5.32
L-index

| # | Paper | IF | Citations |
|-----|--|------|-----------|
| 132 | Cost-utility analysis of adding abiraterone acetate plus prednisone/prednisolone to long-term hormone therapy in newly diagnosed advanced prostate cancer in England: Lifetime decision model based on STAMPEDE trial data. <i>PLoS ONE</i> , 2022 , 17, e0269192 | 3.7 | 1 |
| 131 | Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol. <i>Lancet, The</i> , 2021 , | 4.0 | 18 |
| 130 | Quality of Life in Men With Prostate Cancer Randomly Allocated to Receive Docetaxel or Abiraterone in the STAMPEDE Trial. <i>Journal of Clinical Oncology</i> , 2021 , JCO2100728 | 2.2 | 3 |
| 129 | Transdermal oestradiol for androgen suppression in prostate cancer: long-term cardiovascular outcomes from the randomised Prostate Adenocarcinoma Transcutaneous Hormone (PATCH) trial programme. <i>Lancet, The</i> , 2021 , 397, 581-591 | 4.0 | 6 |
| 128 | Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Prostate Cancer: The Primary Results of the PRONOUNCE Randomized Trial. <i>Circulation</i> , 2021 , 144, 1295-1307 | 16.7 | 13 |
| 127 | Should Patients with High-risk Localised or Locally Advanced Prostate Cancer Receive Abiraterone Acetate in Addition to Androgen Deprivation Therapy? Update on a Planned Analysis of the STAMPEDE Trial. <i>European Urology</i> , 2021 , 80, 522-523 | 10.2 | 1 |
| 126 | The Automated Bone Scan Index as a Predictor of Response to Prostate Radiotherapy in Men with Newly Diagnosed Metastatic Prostate Cancer: An Exploratory Analysis of STAMPEDEB "M1 RT Comparison". <i>European Urology Oncology</i> , 2020 , 3, 412-419 | 6.7 | 5 |
| 125 | Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019. <i>European Urology</i> , 2020 , 77, 508-547 | 10.2 | 155 |
| 124 | Cardiovascular Safety of Degarelix Versus Leuprolide for Advanced Prostate Cancer: The PRONOUNCE Trial Study Design. <i>JACC: CardioOncology</i> , 2020 , 2, 70-81 | 3.8 | 15 |
| 123 | Diagnosis, Staging and Management of Testis Cancer 2020 , 639-652 | | |
| 122 | Maintaining a safe uro-oncological surgical service in the face of the COVID-19 pandemic. <i>Journal of Clinical Urology</i> , 2020 , 205141582095830 | 0.2 | 1 |
| 121 | Genomic Profiles of De Novo High- and Low-Volume Metastatic Prostate Cancer: Results From a 2-Stage Feasibility and Prevalence Study in the STAMPEDE Trial. <i>JCO Precision Oncology</i> , 2020 , 4, 882-897 ^{3,6} | | 8 |
| 120 | Abiraterone in "High-" and "Low-risk" Metastatic Hormone-sensitive Prostate Cancer. <i>European Urology</i> , 2019 , 76, 719-728 | 10.2 | 75 |
| 119 | MRE11 as a Predictive Biomarker of Outcome After Radiation Therapy in Bladder Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019 , 104, 809-818 | 4 | 17 |
| 118 | This is a platform alteration: a trial management perspective on the operational aspects of adaptive and platform and umbrella protocols. <i>Trials</i> , 2019 , 20, 264 | 2.8 | 31 |
| 117 | Importance of non-regional lymph nodes in assigning risk in primary metastatic prostate cancer. <i>BJU International</i> , 2019 , 123, 65-73 | 5.6 | 6 |
| 116 | The management of testis cancer. <i>Surgery</i> , 2019 , 37, 513-523 | 0.3 | |

| | | | |
|-----|--|------|------|
| 115 | Prostate Radiotherapy for Metastatic Hormone-sensitive Prostate Cancer: A STOPCAP Systematic Review and Meta-analysis. <i>European Urology</i> , 2019 , 76, 115-124 | 10.2 | 90 |
| 114 | Prostate radiotherapy in newly diagnosed metastatic prostate cancer. <i>Current Opinion in Urology</i> , 2019 , 29, 620-628 | 2.8 | 2 |
| 113 | Genomic Evaluation of Multiparametric Magnetic Resonance Imaging-visible and -nonvisible Lesions in Clinically Localised Prostate Cancer. <i>European Urology Oncology</i> , 2019 , 2, 1-11 | 6.7 | 17 |
| 112 | Primary Mutational Landscape Linked with Pre-Docetaxel Lactate Dehydrogenase Levels Predicts Docetaxel Response in Metastatic Castrate-Resistant Prostate Cancer. <i>European Urology Focus</i> , 2019 , 5, 831-841 | 5.1 | 11 |
| 111 | Transdermal oestradiol as a method of androgen suppression for prostate cancer within the STAMPEDE trial platform. <i>BJU International</i> , 2018 , 121, 680-683 | 5.6 | 14 |
| 110 | Proteomics in Prostate Cancer Research. <i>Molecular Pathology Library</i> , 2018 , 213-236 | | |
| 109 | Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017. <i>European Urology</i> , 2018 , 73, 178-211 | 10.2 | 313 |
| 108 | Single-Cell Analysis Identifies LY6D as a Marker Linking Castration-Resistant Prostate Luminal Cells to Prostate Progenitors and Cancer. <i>Cell Reports</i> , 2018 , 25, 3504-3518.e6 | 10.6 | 43 |
| 107 | Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial. <i>Lancet, The</i> , 2018 , 392, 2353-2366 | 40 | 510 |
| 106 | Treatment-related toxicity in men who received Intensity-modulated versus 3D-conformal radiotherapy after radical prostatectomy: A national population-based study. <i>Radiotherapy and Oncology</i> , 2018 , 128, 357-363 | 5.3 | 7 |
| 105 | Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy. <i>New England Journal of Medicine</i> , 2017 , 377, 338-351 | 59.2 | 898 |
| 104 | Infrared spectral histopathology using haematoxylin and eosin (H&E) stained glass slides: a major step forward towards clinical translation. <i>Analyst, The</i> , 2017 , 142, 1258-1268 | 5 | 32 |
| 103 | Adding Celecoxib With or Without Zoledronic Acid for Hormone-Naïve Prostate Cancer: Long-Term Survival Results From an Adaptive, Multiarm, Multistage, Platform, Randomized Controlled Trial. <i>Journal of Clinical Oncology</i> , 2017 , 35, 1530-1541 | 2.2 | 37 |
| 102 | Adding abiraterone to androgen deprivation therapy in men with metastatic hormone-sensitive prostate cancer: A systematic review and meta-analysis. <i>European Journal of Cancer</i> , 2017 , 84, 88-101 | 7.5 | 100 |
| 101 | Estimating the Impact of Randomised Control Trial Results on Clinical Practice: Results from a Survey and Modelling Study of Androgen Deprivation Therapy plus Radiotherapy for Locally Advanced Prostate Cancer. <i>European Urology Focus</i> , 2016 , 2, 276-283 | 5.1 | 2 |
| 100 | Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. <i>Lancet, The</i> , 2016 , 387, 1163-77 | 40 | 1115 |
| 99 | Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of aggregate data. <i>Lancet Oncology, The</i> , 2016 , 17, 243-256 | 21.7 | 268 |
| 98 | Failure-Free Survival and Radiotherapy in Patients With Newly Diagnosed Nonmetastatic Prostate Cancer: Data From Patients in the Control Arm of the STAMPEDE Trial. <i>JAMA Oncology</i> , 2016 , 2, 348-57 | 13.4 | 108 |

| | | | |
|----|---|------|-----|
| 97 | Is it safe to insert a testicular prosthesis at the time of radical orchidectomy for testis cancer: an audit of 904 men undergoing radical orchidectomy. <i>BJU International</i> , 2016 , 117, 249-52 | 5.6 | 33 |
| 96 | High-throughput quantum cascade laser (QCL) spectral histopathology: a practical approach towards clinical translation. <i>Faraday Discussions</i> , 2016 , 187, 135-54 | 3.6 | 40 |
| 95 | The management of testis cancer. <i>Surgery</i> , 2016 , 34, 517-526 | 0.3 | 1 |
| 94 | Cardiovascular risk with androgen deprivation therapy for prostate cancer: potential mechanisms. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015 , 33, 464-75 | 2.8 | 24 |
| 93 | Survival with Newly Diagnosed Metastatic Prostate Cancer in the "Docetaxel Era": Data from 917 Patients in the Control Arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019). <i>European Urology</i> , 2015 , 67, 1028-1038 | 10.2 | 255 |
| 92 | External urethral sphincter electromyography in asymptomatic women and the influence of the menstrual cycle. <i>BJU International</i> , 2015 , 116, 423-31 | 5.6 | 12 |
| 91 | Implementing newer agents for the management of castrate-resistant prostate cancer: what is known and what is needed?. <i>BJU International</i> , 2015 , 115, 364-72 | 5.6 | 7 |
| 90 | The Melbourne Consensus Statement on the early detection of prostate cancer. <i>BJU International</i> , 2014 , 113, 186-8 | 5.6 | 50 |
| 89 | Assessment of paraffin removal from prostate FFPE sections using transmission mode FTIR-FPA imaging. <i>Analytical Methods</i> , 2014 , 6, 1028-1035 | 3.2 | 37 |
| 88 | Assessing the challenges of Fourier transform infrared spectroscopic analysis of blood serum. <i>Journal of Biophotonics</i> , 2014 , 7, 180-8 | 3.1 | 47 |
| 87 | Optimisation of an immunohistochemistry method for the determination of androgen receptor expression levels in circulating tumour cells. <i>BMC Cancer</i> , 2014 , 14, 226 | 4.8 | 13 |
| 86 | Quantification of skeletal metastases in castrate-resistant prostate cancer predicts progression-free and overall survival. <i>BJU International</i> , 2014 , 114, E70-E73 | 5.6 | 23 |
| 85 | Advanced prostate cancer: advancing patient care. <i>Trends in Urology & Men's Health</i> , 2014 , 5, 40-42 | 0.3 | |
| 84 | Should centralized histopathological review in penile cancer be the global standard?. <i>BJU International</i> , 2014 , 114, 340-3 | 5.6 | 13 |
| 83 | Automated high-throughput assessment of prostate biopsy tissue using infrared spectroscopic chemical imaging 2014 , | | 7 |
| 82 | Methylation profiling and evaluation of demethylating therapy in renal cell carcinoma. <i>Clinical Epigenetics</i> , 2013 , 5, 16 | 7.7 | 29 |
| 81 | Cardiovascular outcomes in patients with locally advanced and metastatic prostate cancer treated with luteinising-hormone-releasing-hormone agonists or transdermal oestrogen: the randomised, phase 2 MRC PATCH trial (PR09). <i>Lancet Oncology, The</i> , 2013 , 14, 306-16 | 21.7 | 72 |
| 80 | Whole organ cross-section chemical imaging using label-free mega-mosaic FTIR microscopy. <i>Analyst, The</i> , 2013 , 138, 7066-9 | 5 | 22 |

| | | | |
|----|---|------|-----|
| 79 | FTIR microspectroscopy of selected rare diverse sub-variants of carcinoma of the urinary bladder. <i>Journal of Biophotonics</i> , 2013 , 6, 73-87 | 3.1 | 33 |
| 78 | Management of testicular tumours. <i>Surgery</i> , 2013 , 31, 535-542 | 0.3 | |
| 77 | Prostate radiotherapy for men with metastatic disease: a new comparison in the Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy (STAMPEDE) trial. <i>BJU International</i> , 2013 , 111, 697-9 | 5.6 | 26 |
| 76 | Release of macrophage migration inhibitory factor by neuroendocrine-differentiated LNCaP cells sustains the proliferation and survival of prostate cancer cells. <i>Endocrine-Related Cancer</i> , 2013 , 20, 137-49 | 5.7 | 28 |
| 75 | UBE2QL1 is disrupted by a constitutional translocation associated with renal tumor predisposition and is a novel candidate renal tumor suppressor gene. <i>Human Mutation</i> , 2013 , 34, 1650-61 | 4.7 | 13 |
| 74 | Celecoxib plus hormone therapy versus hormone therapy alone for hormone-sensitive prostate cancer: first results from the STAMPEDE multiarm, multistage, randomised controlled trial. <i>Lancet Oncology</i> , 2012 , 13, 549-58 | 21.7 | 86 |
| 73 | A systematic review of neoadjuvant and adjuvant chemotherapy for muscle-invasive bladder cancer. <i>European Urology</i> , 2012 , 62, 523-33 | 10.2 | 162 |
| 72 | FTIR microscopy of biological cells and tissue: data analysis using resonant Mie scattering (RMieS) EMSC algorithm. <i>Analyst</i> , 2012 , 137, 1370-7 | 5 | 108 |
| 71 | Copper modulates zinc metalloproteinase-dependent ectodomain shedding of key signaling and adhesion proteins and promotes the invasion of prostate cancer epithelial cells. <i>Molecular Cancer Research</i> , 2012 , 10, 1282-93 | 6.6 | 10 |
| 70 | Flexible trial design in practice - stopping arms for lack-of-benefit and adding research arms mid-trial in STAMPEDE: a multi-arm multi-stage randomized controlled trial. <i>Trials</i> , 2012 , 13, 168 | 2.8 | 94 |
| 69 | Landmarks in non-hormonal pharmacological therapies for castration-resistant prostate cancer. <i>BJU International</i> , 2012 , 110 Suppl 1, 14-22 | 5.6 | 7 |
| 68 | Genome-wide CpG island methylation analysis implicates novel genes in the pathogenesis of renal cell carcinoma. <i>Epigenetics</i> , 2012 , 7, 278-90 | 5.7 | 50 |
| 67 | Early prostate cancer--which treatment do men prefer and why?. <i>BJU International</i> , 2011 , 107, 1762-8 | 5.6 | 63 |
| 66 | Flexible trial design in practice Dropping and adding arms in STAMPEDE: a multi-arm multi-stage randomised controlled trial. <i>Trials</i> , 2011 , 12, | 2.8 | 7 |
| 65 | Phase II study of conformal hypofractionated radiotherapy with concurrent gemcitabine in muscle-invasive bladder cancer. <i>Journal of Clinical Oncology</i> , 2011 , 29, 733-8 | 2.2 | 123 |
| 64 | Resonant Mie scattering (RMieS) correction of infrared spectra from highly scattering biological samples. <i>Analyst</i> , 2010 , 135, 268-77 | 5 | 283 |
| 63 | When Should Radiotherapy Be Used after Radical Prostatectomy? The RADICALS-RT Trial. <i>British Journal of Medical and Surgical Urology</i> , 2010 , 3, 190-193 | | 4 |
| 62 | Imaging angiogenesis of genitourinary tumors. <i>Nature Reviews Urology</i> , 2010 , 7, 69-82 | 5.5 | 22 |

| | | | |
|----|--|------|-----|
| 61 | SR-FTIR spectroscopy of renal epithelial carcinoma side population cells displaying stem cell-like characteristics. <i>Analyst, The</i> , 2010 , 135, 3133-41 | 5 | 39 |
| 60 | Management of testicular tumours. <i>Surgery</i> , 2010 , 28, 610-616 | 0.3 | |
| 59 | Open to debate. The motion: GnRH antagonists are the new way forward in hormonal therapy. <i>European Urology</i> , 2010 , 57, 534-7 | 10.2 | 2 |
| 58 | Differential complication rates following radical cystectomy in the irradiated and nonirradiated pelvis. <i>European Urology</i> , 2010 , 57, 1058-63 | 10.2 | 33 |
| 57 | Re: Umberto Capitanio, Shahrokh F. Shariat, Hendrik Isbarn, et al. Comparison of oncologic outcomes for open and laparoscopic nephroureterectomy: a multi-institutional analysis of 1249 cases. <i>Eur Urol</i> 2009;56:1-9. <i>European Urology</i> , 2010 , 57, e34-5; author reply e36 | 10.2 | |
| 56 | RMieS-EMSC correction for infrared spectra of biological cells: extension using full Mie theory and GPU computing. <i>Journal of Biophotonics</i> , 2010 , 3, 609-20 | 3.1 | 105 |
| 55 | Hoechst 33342 side population identification is a conserved and unified mechanism in urological cancers. <i>Stem Cells and Development</i> , 2009 , 18, 1515-22 | 4.4 | 55 |
| 54 | Classification of fixed urological cells using Raman tweezers. <i>Journal of Biophotonics</i> , 2009 , 2, 47-69 | 3.1 | 51 |
| 53 | Investigating FTIR based histopathology for the diagnosis of prostate cancer. <i>Journal of Biophotonics</i> , 2009 , 2, 104-13 | 3.1 | 85 |
| 52 | Issues in applying multi-arm multi-stage methodology to a clinical trial in prostate cancer: the MRC STAMPEDE trial. <i>Trials</i> , 2009 , 10, 39 | 2.8 | 95 |
| 51 | Molecular mechanisms of metastasis in prostate cancer. <i>Asian Journal of Andrology</i> , 2009 , 11, 57-67 | 2.8 | 60 |
| 50 | Systemic therapy for advancing or metastatic prostate cancer (STAMPEDE): a multi-arm, multistage randomized controlled trial. <i>BJU International</i> , 2009 , 103, 464-9 | 5.6 | 58 |
| 49 | Cd133: a marker of transit amplification rather than stem cell phenotype in the prostate?. <i>BJU International</i> , 2009 , 103, 856-8 | 5.6 | 8 |
| 48 | A contemporary standard for morbidity and outcome after radical cystectomy. <i>BJU International</i> , 2009 , 104, 628-32 | 5.6 | 24 |
| 47 | Abarelix and other gonadotrophin-releasing hormone antagonists in prostate cancer. <i>BJU International</i> , 2009 , 104, 1580-4 | 5.6 | 21 |
| 46 | Response to Letter to the Editor: National Re-Audit of Urology Outpatient Practice in the UK. <i>British Journal of Medical and Surgical Urology</i> , 2009 , 2, 263-263 | | |
| 45 | CpG methylation profiling in VHL related and VHL unrelated renal cell carcinoma. <i>Molecular Cancer</i> , 2009 , 8, 31 | 42.1 | 56 |
| 44 | Male adnexal tumour of wolffian origin: the first report of metastatic disease. <i>Scandinavian Journal of Urology and Nephrology</i> , 2009 , 43, 253-6 | | 4 |

| | | | |
|----|--|------|-----|
| 43 | Reflection contributions to the dispersion artefact in FTIR spectra of single biological cells. <i>Analyst, The</i> , 2009 , 134, 1171-5 | 5 | 109 |
| 42 | Management of the Spectrum of Hormone Refractory Prostate Cancer (EAU Lecture, The 97th Annual Meeting of the Japanese Urological Association). <i>Japanese Journal of Urology</i> , 2009 , 100, 45 | | |
| 41 | Early hormonal data from a multicentre phase II trial using transdermal oestrogen patches as first-line hormonal therapy in patients with locally advanced or metastatic prostate cancer. <i>BJU International</i> , 2008 , 102, 442-5 | 5.6 | 35 |
| 40 | Aetiology, diagnosis and management of urothelial tumours of the renal pelvis and ureter. <i>BJU International</i> , 2008 , 102, 1302-6 | 5.6 | 8 |
| 39 | Editorial comment on: noninvasive detection of testicular carcinoma in situ in semen using OCT3/4. <i>European Urology</i> , 2008 , 54, 159-60 | 10.2 | |
| 38 | Open to debate. The Motion: all men over the age of 50 should be encouraged to take a 5alpha-reductase inhibitor to prevent prostate cancer. <i>European Urology</i> , 2008 , 53, 1079-83 | 10.2 | 1 |
| 37 | Measurement of elastic properties of prostate cancer cells using AFM. <i>Analyst, The</i> , 2008 , 133, 1498-500 | 5 | 189 |
| 36 | Spectral discrimination of live prostate and bladder cancer cell lines using Raman optical tweezers. <i>Journal of Biomedical Optics</i> , 2008 , 13, 064004 | 3.5 | 65 |
| 35 | Late tissue effects following radiotherapy and neoadjuvant hormone therapy of the prostate measured with quantitative magnetic resonance imaging. <i>Radiotherapy and Oncology</i> , 2008 , 88, 127-34 | 5.3 | 24 |
| 34 | What Does Failure After Surgery or Radiation Mean?. <i>European Urology Supplements</i> , 2008 , 7, 410-415 | 0.9 | 3 |
| 33 | Discrimination of prostate cancer cells and non-malignant cells using secondary ion mass spectrometry. <i>Analyst, The</i> , 2008 , 133, 175-9 | 5 | 25 |
| 32 | Characterization of the Hoechst 33342 side population from normal and malignant human renal epithelial cells. <i>American Journal of Physiology - Renal Physiology</i> , 2008 , 295, F680-7 | 4.3 | 72 |
| 31 | The Biology of Bone Metastases from Prostate Cancer and the Role of Bisphosphonates 2008 , 253-281 | | 1 |
| 30 | Discrimination of prostate cancer cells by reflection mode FTIR photoacoustic spectroscopy. <i>Analyst, The</i> , 2007 , 132, 292-5 | 5 | 41 |
| 29 | Optical artefacts in transflection mode FTIR microspectroscopic images of single cells on a biological support: the effect of back-scattering into collection optics. <i>Analyst, The</i> , 2007 , 132, 750-5 | 5 | 45 |
| 28 | Characterization of benign and malignant prostate epithelial Hoechst 33342 side populations. <i>Prostate</i> , 2007 , 67, 1384-96 | 4.2 | 92 |
| 27 | Radiotherapy and androgen deprivation in combination after local surgery (RADICALS): a new Medical Research Council/National Cancer Institute of Canada phase III trial of adjuvant treatment after radical prostatectomy. <i>BJU International</i> , 2007 , 99, 1376-9 | 5.6 | 109 |
| 26 | Frequency of regulatory T cells in renal cell carcinoma patients and investigation of correlation with survival. <i>Cancer Immunology, Immunotherapy</i> , 2007 , 56, 1743-53 | 7.4 | 157 |

| | | | |
|----|---|------|-----|
| 25 | Complications arising in the final year of life in men dying from advanced prostate cancer. <i>Journal of Palliative Medicine</i> , 2007 , 10, 705-11 | 2.2 | 34 |
| 24 | Direct evidence of lipid translocation between adipocytes and prostate cancer cells with imaging FTIR microspectroscopy. <i>Journal of Lipid Research</i> , 2007 , 48, 1846-56 | 6.3 | 111 |
| 23 | Natural history and treatment of bone complications in prostate cancer. <i>European Urology</i> , 2006 , 49, 429-40 | 10.2 | 64 |
| 22 | A correlation of FTIR spectra derived from prostate cancer biopsies with gleason grade and tumour stage. <i>European Urology</i> , 2006 , 50, 750-60; discussion 760-1 | 10.2 | 99 |
| 21 | Management of the spectrum of hormone refractory prostate cancer. <i>European Urology</i> , 2006 , 50, 428-38; discussion 438-9 | 10.2 | 39 |
| 20 | Management of testicular tumours. <i>Surgery</i> , 2006 , 24, 163-168 | 0.3 | |
| 19 | Skeletal Preservation in Prostate Cancer: The Changing Role of the Urologist. <i>European Urology Supplements</i> , 2006 , 5, 871-872 | 0.9 | 1 |
| 18 | New Research Findings on Clinical Benefits of Bisphosphonates in Patients With Advanced Prostate Cancer. <i>European Urology Supplements</i> , 2006 , 5, 880-885 | 0.9 | 2 |
| 17 | New Clinical Tools for Urologists: Treatment of Bone Loss. <i>European Urology Supplements</i> , 2006 , 5, 877-879 | | |
| 16 | Bone Health in Patients With Prostate Cancer: Monitoring and Diagnosis. <i>European Urology Supplements</i> , 2006 , 5, 873-876 | 0.9 | 2 |
| 15 | The natural history of postoperative renal function in patients undergoing ileal conduit diversion for cancer measured using serial isotopic glomerular filtration rate and 99m technetium-mercaptoacetyltriglycine renography. <i>Journal of Urology</i> , 2006 , 176, 2518-22; discussion 2522 | 2.5 | 30 |
| 14 | The increased rate of prostate specific antigen testing has not affected prostate cancer presentation in an inner city population in the UK. <i>BJU International</i> , 2006 , 97, 266-9 | 5.6 | 22 |
| 13 | Phase I study of conformal radiotherapy with concurrent gemcitabine in locally advanced bladder cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2005 , 61, 420-5 | 4 | 49 |
| 12 | Male adnexal tumour of probable Wolffian duct origin. <i>Scandinavian Journal of Urology and Nephrology</i> , 2005 , 39, 520-2 | | 3 |
| 11 | The molecular staging of prostate cancer. <i>BJU International</i> , 2004 , 94, 1217-20 | 5.6 | 4 |
| 10 | Differential inhibition of invasion and proliferation by bisphosphonates: anti-metastatic potential of Zoledronic acid in prostate cancer. <i>European Urology</i> , 2004 , 46, 389-401; discussion 401-2 | 10.2 | 43 |
| 9 | The combined application of FTIR microspectroscopy and ToF-SIMS imaging in the study of prostate cancer. <i>Faraday Discussions</i> , 2004 , 126, 41-59; discussion 77-92 | 3.6 | 73 |
| 8 | Novel method for the isolation and characterisation of the putative prostatic stem cell. <i>Cytometry</i> , 2003 , 54, 89-99 | | 86 |

| | | | |
|---|---|-----|----|
| 7 | The Biology and Treatment of Bone Metastases in Prostate Cancer 2003 , 931-956 | | |
| 6 | A potential role of heat shock proteins and nicotinamide N-methyl transferase in predicting response to radiation in bladder cancer. <i>International Journal of Cancer</i> , 2002 , 101, 454-60 | 7.5 | 76 |
| 5 | Molecular prediction of progression in patients with conservatively managed prostate cancer. <i>Urology</i> , 2001 , 58, 762-6 | 1.6 | 9 |
| 4 | Scatter factor influences the formation of prostate epithelial cell colonies on bone marrow stroma in vitro. <i>Clinical and Experimental Metastasis</i> , 1999 , 17, 333-40 | 4.7 | 21 |
| 3 | Interaction of prostate epithelial cells from benign and malignant tumor tissue with bone-marrow stroma. <i>Prostate</i> , 1998 , 34, 203-13 | 4.2 | 32 |
| 2 | Primary prostatic epithelial cell binding to human bone marrow stroma and the role of alpha2beta1 integrin. <i>Clinical and Experimental Metastasis</i> , 1997 , 15, 218-27 | 4.7 | 47 |
| 1 | The effects of orchidectomy on skeletal metabolism in metastatic prostate cancer. <i>Scandinavian Journal of Urology and Nephrology</i> , 1993 , 27, 475-83 | | 32 |